Based on FDA recommendations, DPP-4 inhibitors have been tested in large clinicaloutcome trials: The SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular OutcomesRecorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction53)5, the EXAMINE (Cardiovascular Outcomes Study of Alogliptin inPatients with Type 2 Diabetes and Acute Coronary Syndrome)10 and theTECOS7 trials. This evidence concerns the gene DPP4 and acute coronary syndrome.